RU2726411C2 - Вакцинная композиция и ее применения - Google Patents

Вакцинная композиция и ее применения Download PDF

Info

Publication number
RU2726411C2
RU2726411C2 RU2017137502A RU2017137502A RU2726411C2 RU 2726411 C2 RU2726411 C2 RU 2726411C2 RU 2017137502 A RU2017137502 A RU 2017137502A RU 2017137502 A RU2017137502 A RU 2017137502A RU 2726411 C2 RU2726411 C2 RU 2726411C2
Authority
RU
Russia
Prior art keywords
crm
her2
neu
fusion
alum
Prior art date
Application number
RU2017137502A
Other languages
English (en)
Russian (ru)
Other versions
RU2017137502A (ru
RU2017137502A3 (enExample
Inventor
Урсула ВИДЕРМАНН
Original Assignee
Биолайф Сайенс Клд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901375A external-priority patent/AU2015901375A0/en
Application filed by Биолайф Сайенс Клд Лимитед filed Critical Биолайф Сайенс Клд Лимитед
Publication of RU2017137502A publication Critical patent/RU2017137502A/ru
Publication of RU2017137502A3 publication Critical patent/RU2017137502A3/ru
Application granted granted Critical
Publication of RU2726411C2 publication Critical patent/RU2726411C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017137502A 2015-04-17 2016-04-15 Вакцинная композиция и ее применения RU2726411C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901375A AU2015901375A0 (en) 2015-04-17 A vaccine composition and uses thereof
AU2015901375 2015-04-17
PCT/AU2016/050275 WO2016164980A1 (en) 2015-04-17 2016-04-15 A vaccine composition and uses thereof

Publications (3)

Publication Number Publication Date
RU2017137502A RU2017137502A (ru) 2019-05-17
RU2017137502A3 RU2017137502A3 (enExample) 2019-09-16
RU2726411C2 true RU2726411C2 (ru) 2020-07-14

Family

ID=57125491

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017137502A RU2726411C2 (ru) 2015-04-17 2016-04-15 Вакцинная композиция и ее применения

Country Status (13)

Country Link
US (1) US10532090B2 (enExample)
EP (1) EP3283105B1 (enExample)
JP (1) JP6957448B2 (enExample)
KR (1) KR102372615B1 (enExample)
CN (1) CN108025061B (enExample)
AU (1) AU2016250289B2 (enExample)
ES (1) ES2908071T3 (enExample)
NZ (1) NZ736194A (enExample)
RS (1) RS63080B1 (enExample)
RU (1) RU2726411C2 (enExample)
SG (1) SG11201708247XA (enExample)
TW (1) TWI740823B (enExample)
WO (1) WO2016164980A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3723792A2 (en) * 2017-12-11 2020-10-21 Medizinische Universität Wien A method of producing a vaccine composition and uses thereof
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ ワクチン組成物およびその使用
CA3202133A1 (en) * 2020-12-16 2022-06-23 Martin Gohlke Method for quantifying cpg-containing oligonucleotides in formulations comprising alum

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
WO2011020604A1 (en) * 2009-08-18 2011-02-24 Pevion Biotech Ag Multiepitope vaccine for her2/neu-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
ES2348312T3 (es) 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
SI2668959T1 (sl) * 2012-05-31 2015-03-31 Innavirvax Genopole Enterprises Imunogenske spojine, ki vsebujejo HIV gp41 peptid, spojen z nosilnim proteinom CRM197
US20170196953A1 (en) * 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
WO2011020604A1 (en) * 2009-08-18 2011-02-24 Pevion Biotech Ag Multiepitope vaccine for her2/neu-associated cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Danishefsky S. et al. Development of Globo-H cancer vaccine // Acc Chem Res. 2015 Mar 17;48(3):643-52. *
Danishefsky S. et al. Development of Globo-H cancer vaccine // Acc Chem Res. 2015 Mar 17;48(3):643-52. Jasinska J et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu // Int J Cancer. 2003 Dec 20;107(6):976-83. Wagner S. et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice // Breast Cancer Res Treat. 2007 Nov;106(1):29-38. Wiedermann U. et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study // Breast Cancer Res Treat. 2010 Feb;119(3):673-83. *
Jasinska J et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu // Int J Cancer. 2003 Dec 20;107(6):976-83. *
Wagner S. et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice // Breast Cancer Res Treat. 2007 Nov;106(1):29-38 *
Wiedermann U. et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study // Breast Cancer Res Treat. 2010 Feb;119(3):673-83 *

Also Published As

Publication number Publication date
US10532090B2 (en) 2020-01-14
EP3283105B1 (en) 2022-01-26
RS63080B1 (sr) 2022-04-29
RU2017137502A (ru) 2019-05-17
TWI740823B (zh) 2021-10-01
HK1248536A1 (zh) 2018-10-19
EP3283105A4 (en) 2018-12-19
BR112017021981A2 (pt) 2018-07-10
TW201705978A (zh) 2017-02-16
RU2017137502A3 (enExample) 2019-09-16
KR102372615B1 (ko) 2022-03-08
CN108025061A (zh) 2018-05-11
AU2016250289B2 (en) 2017-03-02
JP2018511659A (ja) 2018-04-26
AU2016250289A1 (en) 2017-01-05
KR20180003560A (ko) 2018-01-09
JP6957448B2 (ja) 2021-11-02
ES2908071T3 (es) 2022-04-27
NZ736194A (en) 2022-08-26
SG11201708247XA (en) 2017-11-29
EP3283105A1 (en) 2018-02-21
WO2016164980A1 (en) 2016-10-20
CN108025061B (zh) 2022-02-15
US20170119867A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US10166276B2 (en) Compositions and methods for treatment of non-hodgkins lymphoma
US20170143810A1 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CN105085684B (zh) Pcsk9靶向重组疫苗设计及其应用
ES2639577T3 (es) Vacuna para la prevención de la recurrencia del cáncer de mama
JP6957448B2 (ja) ワクチン組成物およびその使用
US12311019B2 (en) Vaccine composition and uses thereof
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
AU2014296038B2 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
US20210346484A1 (en) Method of producing a vaccine composition and uses thereof
US11154599B2 (en) Her2/neu immunogenic composition
TWI784985B (zh) 瘧疾疫苗
JP7616662B2 (ja) 癌の予防、治療及び／または検出において使用するための新規ペプチドベースの化合物
BR112017021981B1 (pt) Composição de vacina e usos da mesma
US20090028847A1 (en) Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
HK1248536B (en) A vaccine composition and uses thereof